Anadys Pharmaceuticals, Inc.
The people of Anadys are committed to advancing patient care by discovering, developing, and commercializing novel and powerful anti-infective medicines. Anadys is focused on the discovery and development of small molecule therapeutics for the treatment of infectious disease, including hepatitis C and bacterial infections. The company's lead program for the treatment of hepatitis C is currently in Phase IB testing. Anadys also has a broad portfolio of antiviral and antibacterial programs directed at novel targets, intervention points and mechanisms of action. With an integrated suite of technologies and capabilities, including Riboproteomics, ATLAS and structure-based drug design through a world-class medicinal chemistry team, Anadys is capable of quickly optimizing lead compounds for use in preclinical and clinical testing. The company's goal is to build a strong and continual pipeline of novel and powerful drug candidates directed to advance patient care.
Basbaum
Andre
A
Senior Manager, Corporate Development & Strategy, Anadys Pharmaceuticals, Inc., 9050 Camino Santa Fe, San Diego, CA 92121, USA. basbaum@anadyspharma.com
D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D001424:Bacterial Infections / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism; D015507:Drugs, Investigational / Q000627:therapeutic use*; D006801:Humans; D013678:Technology, Pharmaceutical / Q000295:instrumentation / Q000379:methods*
D000900:Anti-Bacterial Agents; D015507:Drugs, Investigational